Pharma Mar (PHMMF) Stock Price, News & Analysis

Company Overview

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Key Stats

• Today's Range: $96.20 to $96.20
• 50-Day Range: $80.91 to $102.08
• 52-Week Range: $34.26 to $105.60
• Volume: 74 shs
• Average Volume: 943 shs
• Market Capitalization: $1.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

PHMMF Stock Analysis - Frequently Asked Questions

How have PHMMF shares performed this year?

Pharma Mar's stock was trading at $81.07 at the start of the year. Since then, PHMMF stock has increased by 18.7% and is now trading at $96.20.
View the best growth stocks for 2025 here.

How do I buy shares of Pharma Mar?

Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/28/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PHMMF
• Previous Symbol: NASDAQ:PHMMF
• CIK: N/A
• Web: www.pharmamar.com
• Phone: (491) 846-6000
• Fax: 34-91-846-6001
• Employees: 509
• Year Founded: 1986

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 2.55
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: $171.15 million
• Price / Sales: 10.12
• Cash Flow: $0.42 per share
• Price / Cash Flow: 231.27
• Book Value: $11.62 per share
• Price / Book: 8.28

Miscellaneous

• Outstanding Shares: 18,010,000
• Free Float: N/A
• Market Cap: $1.73 billion
• Optionable: Not Optionable
• Beta: 0.25